The president and CEO of the Biotechnology Industry Organization, James Greenwood, tells the Boston Globe that the biotech companies will, for the most part, survive the recession. As a whole, he says, the industry has just started to make money, though because of the economy, there is a risk of some companies losing out. Greenwood also discusses generic biologics and data exclusivity as well as healthcare reform. The R&D Direction Insider blog adds that regarding biosimilars, "it's hard to imagine a soon-to-be compromise that some are predicting."
That's What They Said About Banking
May 12, 2009